Abstract: The present disclosure relates to methods for treating infectious disorders. In particular, the disclosure provides BTN3A activating antibodies, and their use in treating infectious disorders in a human subject in need thereof, such as disorders caused by SARS-Cov2 or Coxiella burnetii infection.

Abstract: The disclosure is directed at providing molecular tools and methods for transgenes integration in the genome of host cells, in particular tools and method enabling a transposition-dependent expression of the transgene, thereby facilitating identification and selection of effectively transformed hosts.

Abstract: Isolated anti-human CD45RC antibodies or binding fragments thereof, nucleic acids and expression vector encoding the same, compositions including the same, and uses thereof as medicaments, including for the prevention and/or treatment of CD45RChigh-related diseases (including autoimmune diseases, undesired immune responses, monogenic diseases, and lymphoma or cancer), in particular for use in preventing and/or treating graft-versus-host disease (GVHD).

Abstract: The present invention relates to methods for predicting the risk of developing pulmonary colonization/infection by P. aeruginosa. The inventors analyzed the respiratory tract microbiota from 65 patients sputum samples and compared microbiota data. The inventors found that patients that will remain uninfected from P. aeruginosa exhibited 3-fold higher abundance of Porphyromonas catoniae compared to the other groups. In particular, the present invention relates to a method for predicting the risk of developing pulmonary colonization/infection by P. aeruginosa in a subject suffering from cystic fibrosis (CF) comprising measuring the abundance of Porphyromonas catoniae in a biological sample obtained from said subject.

Abstract: The present invention relates to compounds of formula (I): for use as peripheral NMDA receptor antagonists.

Abstract: A new peptide and its use as a vector for the transport of molecules after conjugation through cellular barriers for the diagnosis, prognosis or treatment of pathologies of the central nervous system (CNS).

Abstract: The present invention relates to a method for analyzing the platelets present in a blood sample, said method comprises the steps of (a) adding to said sample a ligand which binds to the MCH I coupled to a fluorochrome, (b) measuring the mean fluorescence intensity of the platelets (MFIplatelets) with a flow cytometer and c) measuring the mean “Forward Scatter” parameter (FSC) with said flow cytometer and determining the MFIplatelets/FSC ratio. The invention also relates to an in vitro method for diagnosing a peripheral or central thrombocytopenia in a subject.

Abstract: FGFR3-related chondrodysplasias represent a group of rare diseases. Among them, achondroplasia, a nonlethal form of chondrodysplasia, is the most common type of dwarfism. The mutation, which produce an increase of FGFR3 function, affects many tissues, most strikingly the cartilaginous growth plate and bone in the growing skeleton, leading to a variety of manifestations and complications. In attempt to find a new therapeutic approach for FGFR3-related chondrodysplasia, the inventors purified (?)-epicatechin from T. cacao and showed that (?)-epicatechin treatment significantly increases the length of the Fgfr3Y367C/+ femurs comparing to Fgfr3+/+ femurs and improves the whole growth plate cartilage. The present invention thus relates to the use of (?)-epicatechin for the treatment of FGFR3-related chondrodysplasias.

Abstract: The present invention relates to antibodies having specificity for BTN2A and uses thereof, in particular for the treatment of cancer.

Abstract: The present invention relates to the allergy field. Several independent groups have recently investigated the implication of PCSK9 on inflammation and sepsis but none of them have determined its impact on allergies and/or asthma which is a global health burden. Inventors have obtained preliminary data on wild-type (PCSK9+/+) or PCSK9-deficient mice (PCSK9?/?) and shown that, under basal condition and in the absence of a particular stimulus, PCSK9 deficiency significantly increases the percentage of regulatory T cells in the spleen, the mesenteric lymph nodes and Peyer's patches. Moreover, inventors have shown the effect of allergic challenge on primary human bronchial epithelial cells on PCSK9 expression and secretion. Very interestingly, their first results obtained by Q-PCR showed that HDM and LPS increase PCSK9 mRNA levels. Accordingly, the present invention relates to inhibitors of PCSK9 for use in the treatment of asthma and/or allergic disease, such as food allergy.

Abstract: The present invention relates to a method for predicting neurodegenerative decline and/or its severity for a patient, especially of cognitive impairment (CI). Strokes and Parkinson's disease are frequently associated with occurrence of long-term cognitive impairment or dementia with still incompletely resolved mechanisms. The discovery of diagnostic and predictive biomarkers thus remains a major challenge. The method of the invention uses radiomics corresponding to texture features extracted from a plurality of previously-acquired medical brain images and correlated with previously-acquired clinical and/or biological data. A classifier is trained beforehand for learning these radiomics, and then operated on radiomics computed from at least one brain image of a patient to generate a score representative of its risks of neurodegenerative decline. By applying this method on a cohort of 160 MCI and non-MCI patients, the inventors show that MCI patients could be early predicted with a mean accuracy of 88%.

Abstract: An adhesive composition including a calcium phosphate ceramic selected from tetracalcium phosphate and alpha-tricalcium phosphate, phosphorylated serine, polydopamine, and an aqueous solvent. Also, a kit for preparing the adhesive composition, which includes the calcium phosphate ceramic, phosphorylated serine, and polydopamine and a method for preparing the adhesive composition, as well as the uses thereof.

Abstract: Disclosed is an automatic image analysis method that can be used to automatically recognise at least one rare characteristic in an image to be analysed. The method comprises a learning phase during which at least one convolutional neural network is trained to recognise characteristics, a parameter space of dimension n, in which n?2, is constructed from at least one intermediate layer of the network, a presence probability function is determined for each characteristic in the parameter space from a projection of reference images in the parameter space. During a phase of analysing the image to be analysed, the method comprises a step of recognising the at least one rare characteristic in the image to be analysed on the basis of the presence probability function determined for the at least one rare characteristic.

Abstract: The invention relates to a nucleic acid construct for gene therapy of FGF-23 related hypophosphatemic diseases, in particular gene therapy directed to muscle, liver or hematopoietic tissue, more particularly liver tissue. The invention relates also to a vector comprising the nucleic acid construct, and their use for the treatment of FGF-23 related hypophosphatemic diseases, in particular XLH, by gene therapy.

Abstract: The present invention relates to the fields of medicine and in particular cancer treatment. The invention more specifically relates to new compounds which are typically for use as a medicament. In particular, the invention relates to the use of these new compounds for increasing the presentation, typically the production and presentation, of Pioneer Translation Products (PTPs)-derived antigens by cells, in particular cancer cells, or changing the immunopeptidome, in a subject, and inducing or stimulating an immune response in the subject. The present disclosure also relates to uses of such compounds, in particular to prepare a pharmaceutical composition and/or to allow or improve the efficiency of a therapy in a subject in need thereof. The invention also discloses methods for treating a disease, in particular cancer, for preventing or treating cancer metastasis and/or cancer recurrence, in a subject.

Abstract: The invention relates to a device (10) for selective regionalization of pulmonary aeration, intended to apply a vacuum over a posterolateral part of a patient's chest wall, said device comprising a rigid or semi-rigid shell (11) intended to selectively surround a posterior part of the patient's chest wall, and a layer of honeycomb material (12) covering an internal wall (13) of the rigid shell, intended to be in contact with the patient's chest wall, said shell comprising at least one through hole (14), intended to be connected to a negative pressure generator.

Abstract: The present invention relates to the field of therapeutic treatment of polycystic ovary syndrome (PCOS). Polycystic ovary syndrome, PCOS, is the most common female reproductive disorder against which no therapeutic solution is available, beyond changes in the lifestyle. The inventors have now shown by using in vivo preclinical models, that individuals affected with PCOS have an abnormal elevated production of GnRH and that this elevated production of GnRH was transmitted to their offspring that also develop PCOS. Further, by examining AMH levels in a cohort of pregnant PCOS and control women, the inventors have found that AMH concentrations are significantly higher in PCOS women as compared to healthy women during the second trimester of gestation. These unexpected findings has allowed conceiving both prevention and treatment therapeutic strategies based on the administration of GnRH antagonists.

Abstract: An immunogenic product including a cytokine conjugated with a carrier protein, wherein the cytokine is selected from the group including IL-4, IL-13 and mixtures thereof, and wherein the carrier protein is CRM197. Further, a method for manufacturing the immunogenic product. Also, the therapeutic use of the immunogenic product for treating an inflammatory disorder associated with aberrant IL-4 and/or IL-13 expression or activity.

Abstract: Sarbecoviruses (lineage B of genus Betacoronavirus) have caused two major outbreaks during the past two decades: SARS-CoV in 2003, and SARS-CoV-2 from 2019. SARS-CoV-2 vaccines will be essential to reduce morbidity and mortality. Therefore, universal vaccines against this class of viruses are key to ending the current pandemic, but also for preventing additional emergent variations and future outbreaks of SARS-like viruses that are continuously found from nature reservoirs. Now, the inventors produced an antibody that is directed against a surface antigen (i.e., CD40) of an antigen presenting cell (i.e., dendritic cell) wherein the heavy chain is conjugated or fused to a protein N polypeptide of SAR-CoV-2 and the light chain is fused to a RBD polypeptide. In particular, the inventors show that said antibody could elicit immune responses against Sarbecoviruses.

Abstract: The present invention relates to a virus-derived particle comprising one or more Cas protein(s), as well as to kits and methods using the same for altering a target nucleic acid.